Table 2:
TDP type-α | TDP type-β | P-value | |
---|---|---|---|
(N = 131) | (N = 110) | ||
HpScI, n (%) | 78 (60%) | 16 (15%) | <0.001 |
LBD, n (%) | 32 (36%) | 36 (35%) | >0.99 |
TDP 6 stages, n (%) | <O.001 | ||
Stage 1 | 2 (2%) | 31 (28%) | |
Stage 2 | 7 (5%) | 48 (44%) | |
Stage 3 | 11 (8%) | 13 (12%) | |
Stage 4 | 46 (35%) | 13 (12%) | |
Stage 5 | 42 (32%) | 4 (4%) | |
Stage 6 | 23 (18%) | 1 (1%) | |
Braak, n (%) | 0.03 | ||
Braak 1 | 2 (2%) | 0 (0%) | |
Braak 2 | 5 (4%) | 0 (0%) | |
Braak 3 | 5 (4%) | 1 (1%) | |
Braak 4 | 17 (13%) | 19 (17%) | |
Braak 5 | 43 (33%) | 27 (25%) | |
Braak 6 | 59 (45%) | 63 (57%) | |
Amyloid, n (%) | 0.14 | ||
Amyloid 0 | 11 (9%) | 2 (2%) | |
Amyloid 1 | 9 (7%) | 9 (8%) | |
Amyloid 2 | 35 (27%) | 28 (26%) | |
Amyloid 3 | 74 (57%) | 70 (64%) | |
Vascular disease, n (%) | 28 (31%) | 27 (26%) | 0.52 |
Data shown are n (%) or median (range). P-values for categorical variables are from Fisher’s exact tests, and Wilcoxon Rank Sum tests for continuous variables.
HpScl = hippocampal sclerosis; LBD = Lewy body disease;